Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-11
2006-04-11
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000, C514S443000
Reexamination Certificate
active
07026344
ABSTRACT:
Sickle cell disease is treated by administering a 5-lipoxygenase inhibitor.
REFERENCES:
patent: 4873259 (1989-10-01), Summers, Jr. et al.
patent: 5629337 (1997-05-01), Gray
patent: 5817684 (1998-10-01), Fleisch et al.
patent: WO 96/20936 (1996-07-01), None
“The 5-Lipoxygenase Inhibitory Activity of Zileuton in In Vitro and In Vivo Models of Antigen-Induced Airway Anaphylaxis”, Malo et al., Pulmonary Pharmacology, abstract, vol. 7, Issue 2, Apr. 1994, pp. 73-79.
“Zileuton: A Potential New Treatment Approach For Acute Chest Syndrome”, Dixon et al., Bloood, abstract, Nov. 2000, vol. 96, No. 11, Par 1, pp. 10a.
“The Effect of 5-Lipoxygenase Inhibition by Zileuton on Platelet-Activating-Factor-Induced Pulmonary Abnormalties in Mild Asthma”, Gomez et al, Am J Resp Crit Care Med 1998, vol. 157, pp. 1559-1564.
“Lipoxygenase Inhibitors as Potential Cancer Chemopreventives”, Steele et al., Cance Epidemiology, Bioarkers and Prevention, vol. 8, May 1999, pp. 467-483.
Samuel Charache et al., “Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia”, The New England Journal of Medicine, May 18, 1995, vol. 332, No. 20, pp. 1-3.
Richard D. Moore et al., “Cost-Effectiveness of Hydroxyurea in Sickle Cell Anemia”, American Journal of Hematology, 64:26-31, 2000, pp. 26-31.
Fact Sheet, “Hydroxyurea in Pediatric Patients with Sickle Cell Disease”, Jun. 1998.
James Eckman, M.D., et al., “Sickle Cell Information Center Protocols”, Hydroxyurea Therapy Oct. 15, 1997, pp. 1-6.
Allan Platt PA-C et al., “Sicke Cell Research” The Sickle Cell Information Center, Web Update, Aug. 1999, pp. 1-6.
“The Acute Chest Syndrome of Sickle Cell Disease”, The New England Journal of Medicine, Jun. 22, 2000, vol. 342, No. 25, pp. 1-3.
“Hydroxyurea and Sickle Cell Crisis”, The New England Journal of Medicine, Oct. 12, 1995, vol. 333, No. 15, pp. 1-5.
Elliott P. Vichinsky et al., “Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease”, The New England Journal of Medicine, Jun. 22, 2000, vol. 342, No. 25, pp. 1-2.
Graham R. Serjeant, MD, FRCP, “The Geography of Sickle Cell Disease: Opportunities For Understanding Its Diversity”, May 1994.
Jeffrey D. Hasday et al., “Anti-Inflammatory Effects of Zileuton in a Subpopulation of Allergic Asthmatics”, Am J Respir Crit Care Med, vol. 161, 2000, pp. 1229-1236.
Randy L. Bell et al., “Optimization of the Potency and Duration of Action of N-Hydroxyurea 5-Lipoxygenase Inhibitors”, The Journal of Pharmacology and Experimental Therapeutics, vol. 272, No. 2, 1995, pp. 724-731.
“Companies with Ongoing Sicke Cell Research, Treatment Development, or Related Web Sites”, The Sickle Cell Information Center, pp. 1-10.
Walid M. Awni et al, “Pharmacokinetics and Pharmacodynamics of Zileuton After Oral Administration of Single and Multiple Dose Regimens of Zileuton 600mg in Healthy Volunteers”, Clin Pharmacokinet 29, Suppl 2, 1995, pp. 23-33.
Rene A. Braeckman et al., “The Pharmacokinetics of Zileuton in Healthy Young and Elderly Volunteers”, Clin. Pharmacokinet 29, Suppl. 2, 1995, pp. 42-48.
Zileuton (Systemic), Medline plus Health Information, pp. 1-4.
“Hydroxyurea (Systemic)”, Medline plus Health Information, pp. 1-6.
The Leukotriene Pathway 1-3, Abbott Laboratories, pp. 1-2, 1-3.
“It's Time to Rethink Your Approach to Treating the Components of Chronic Asthma”, Abbott Laboratories, pp. 1-4.
Zyflo Flimtab (zileuton tablets), pp. 1-9.
Connolly Bove & Lodge & Hutz LLP
Kwon Brian S.
Low Christopher S. F.
South Alabama Medical Science Foundation
LandOfFree
Treating sickle cell disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating sickle cell disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating sickle cell disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598849